A randomized controlled trial of antipsychotic combination in acute-phase schizophrenia

Not Applicable

• Conditions: schizophrenia

• Registration Number: JPRN-UMIN000003531
• Lead Sponsor: Faculty of Medicine, Juntendo University

Brief Summary

Seventy-eight patients completed 2 weeks of treatment, and divided into early responders to risperidone (n=52), and early non-responders to risperidone (the RIS+OLZ group, n=13; the RIS+RIS group, n=13). At 10 weeks, there was no significant difference in the achievement of >=50% response between the two early non-responder groups (23% vs. 23%). Remarkably, difference in time to treatment discontinuation for any cause between early responders to risperidone and the RIS+OLZ group was not found (8.6 weeks [95%CI: 7.9-9.3] vs. 7.9 weeks [6.3-9.5], P=0.37) although that was significantly longer in early responders to risperidone than in the RIS+RIS group (8.6 weeks [7.9-9.3] vs. 6.8 weeks [5.2-8.4], P=0.018).

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-31
• Study Completion: 2011-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

1) obvious complications such as liver dysfunction, renal dysfunction, heart failure, and respiratory failure 2) diabetes mellitus 3) Patients who were pregnant or who want to become pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified